Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in CRISPR Therapeutics AG, Xencor or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how CRISPR Therapeutics AG, Xencor and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About CRISPR Therapeutics AG, Xencor and Inc.

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company’s CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company’s lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient’s hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; XmAb942, which is in clinical development for patients with Crohn’s disease and ulcerative colitis; Plamotamab, a bispecific T-cell, which is in Phase Ib study to treat rheumatoid arthritis; and XmAb657 for patients with idiopathic inflammatory myopathies. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat metastatic castration-resistant prostate cancer; Obexelimab, an antibody to treat patients with autoimmune diseases; Tobevibart, a treatment for chronic hepatitis Delta; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Novartis, an antibody drug candidate that uses XmAb Fc technologies; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.

Latest Biotechnology and CRISPR Therapeutics AG, Xencor, Inc. Stock News

As of August 20, 2026, CRISPR Therapeutics AG had a $5.6 billion market capitalization, compared to the Biotechnology median of $286.3 million. CRISPR Therapeutics AG’s stock is up 10.8% in 2026, up 7.6% in the previous five trading days and up 7.29% in the past year.

Currently, CRISPR Therapeutics AG does not have a price-earnings ratio. CRISPR Therapeutics AG’s trailing 12-month revenue is $13.4 million with a % net profit margin. As of August 20, 2026, CRISPR Therapeutics AG has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $-4.447 per share for the current fiscal year. CRISPR Therapeutics AG does not currently pay a dividend.

As of August 20, 2026, Xencor, Inc. had a $2.0 billion market cap, putting it in the 53rd percentile of all stocks. Xencor, Inc.’s stock is up 76.4% in 2026, up 17.4% in the previous five trading days and up 255.73% in the past year.

Currently, Xencor, Inc. does not have a price-earnings ratio. Xencor, Inc.’s trailing 12-month revenue is $105.0 million with a -155.6% net profit margin. Year-over-year quarterly sales growth most recently was 17.4%. Analysts expect adjusted earnings to reach $-3.114 per share for the current fiscal year. Xencor, Inc. does not currently pay a dividend.

How We Compare CRISPR Therapeutics AG, Xencor and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at CRISPR Therapeutics AG, Xencor and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

CRISPR Therapeutics AG, Xencor and Inc. Growth Grades

Company	Ticker	Growth
CRISPR Therapeutics AG	CRSP	F
Xencor, Inc.	XNCR	F

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

CRISPR Therapeutics AG has a Growth Score of 7, which is Very Weak. Xencor, Inc. has a Growth Score of 9, which is Very Weak.

The Growth Stock Winner: No Clear Winner

Neither CRISPR Therapeutics AG, Xencor or Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if CRISPR Therapeutics AG, Xencor or Inc. is the better investment when it comes to sustainable growth.

CRISPR Therapeutics AG, Xencor and Inc.’s Momentum Grades

Company	Ticker	Momentum
CRISPR Therapeutics AG	CRSP	B
Xencor, Inc.	XNCR	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

CRISPR Therapeutics AG has a Momentum Score of 56, which is Average. Xencor, Inc. has a Momentum Score of 99, which is Very Strong.

The Momentum Grade Winner: Xencor, Inc.

As you can clearly see from the Momentum Grade breakdown above, Xencor, Inc. is considered to have stronger momentum compared to CRISPR Therapeutics AG. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Xencor, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

CRISPR Therapeutics AG, Xencor and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
CRISPR Therapeutics AG	CRSP	C
Xencor, Inc.	XNCR	B

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

CRISPR Therapeutics AG has a Earnings Estimate Score of 58, which is Neutral. Xencor, Inc. has a Earnings Estimate Score of 67, which is Positive.

The Earnings Estimate Revisions Grade Winner: Xencor, Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Xencor, Inc. has a better Earnings Estimate Revisions Grade than CRISPR Therapeutics AG. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Xencor, Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other CRISPR Therapeutics AG, Xencor and Inc. Grades

In addition to Estimate Revisions, Growth and Momentum, A+ Investor also provides grades for Value and Quality.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether CRISPR Therapeutics AG, Xencor and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, CRISPR Therapeutics AG, Xencor or Inc. Stock?

Overall, CRISPR Therapeutics AG stock has a Growth Score of 7, Momentum Score of 56 and Estimate Revisions Score of 58.

Xencor, Inc. stock has a Growth Score of 9, Momentum Score of 99 and Estimate Revisions Score of 67.

Comparing CRISPR Therapeutics AG, Xencor and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.